Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

101. Management of osteoporosis in patients living with HIV - a systematic review and meta-analysis

Management of osteoporosis in patients living with HIV - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

102. Selection of anti-osteoporosis drugs in patients with osteoporosis during initial drug treatment

Selection of anti-osteoporosis drugs in patients with osteoporosis during initial drug treatment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

103. Review and meta-analyses of interventions to improve osteoporosis management

Review and meta-analyses of interventions to improve osteoporosis management Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

104. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

105. The association between atopic dermatitis and osteoporosis

The association between atopic dermatitis and osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

106. A systematic review of the economic burden of osteoporosis worldwide

A systematic review of the economic burden of osteoporosis worldwide Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

107. An association analysis of miRNA with osteoporosis: a systematic review

An association analysis of miRNA with osteoporosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

108. Vitamin E intake in relation to osteoporosis and bone mineral density: a systematic review and meta analysis

Vitamin E intake in relation to osteoporosis and bone mineral density: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

109. Efficacy comparison of denosumab versus bisphosphonates in patients with low bone mass or osteoporosis

Efficacy comparison of denosumab versus bisphosphonates in patients with low bone mass or osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

110. Effect of thyroidectomy on bone density and osteoporosis : A meta-analysis of high-quality studies

Effect of thyroidectomy on bone density and osteoporosis : A meta-analysis of high-quality studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

111. Gout and risk of osteoporosis: a systematic review and meta-analysis

Gout and risk of osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

112. The efficacy of prebiotics, probiotics and synbiotics in the prevention and treatment of osteoporosis: a meta-analysis of randomized controlled trials

The efficacy of prebiotics, probiotics and synbiotics in the prevention and treatment of osteoporosis: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

113. Meta-analysis of high risk factors for secondary osteoporosis in patients with systemic lupus erythematosus

Meta-analysis of high risk factors for secondary osteoporosis in patients with systemic lupus erythematosus Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

114. A protocol for a systematic review comparing the effects of active vitamin D and plain vitamin D on fracture risk in patients with osteoporosis

A protocol for a systematic review comparing the effects of active vitamin D and plain vitamin D on fracture risk in patients with osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

115. Mandibular textural features on dental imaging exams of individuals with osteoporosis

Mandibular textural features on dental imaging exams of individuals with osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

116. Efficacy and safety of Zuogui Pill in treating osteoporosis: study protocol of a systematic review

Efficacy and safety of Zuogui Pill in treating osteoporosis: study protocol of a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

117. Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults)

Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) NHS England » Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) Search Search Menu Interim Clinical Commissioning Policy Statement: Teriparatide for Osteoporosis in Men (Adults) Document first published: 6 July 2018 Page updated: 6 July 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of treatment for Osteoporosis

2018 NHS England

118. Prevention and treatment of osteoporosis in women

Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women | British Menopause Society Search for: Summary consensus statement Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women 2018-11-09T17:16:44+01:00 Summary The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects 1 in 3 women. This guidance regarding (...) oestrogen and non oestrogen based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up to date evidence based information and targeted to individual women’s needs. Summary practice points HRT reduces the risk of both spine and hip as well as other osteoporotic fractures. Oestrogen remains the treatment of choice for osteoporosis prevention in menopausal women, and especially in those with premature ovarian

2018 British Menopause Society

119. Osteoporosis — identification and management in primary care

Osteoporosis — identification and management in primary care '); } else { document.write(' '); } ACE | Osteoporosis — identification and management in primary care Search > > Osteoporosis — identification and management in primary care - Osteoporosis — identification and management in primary care Published on 7 November 2018 This Appropriate Care Guide (ACG) highlights the importance of early identification of patients at risk of osteoporosis or fragility fracture. Guidance is provided on risk (...) assessment, correct diagnosis, and management considerations. It also includes a supplementary guide on treatment options and bisphosphonates treatment monitoring. Download the PDF below to access the full ACG. Key Messages 1. Assess osteoporosis risk in post-menopausal women, and men 65 years and older. 2. Diagnose osteoporosis in patients with a fragility fracture or DXA BMD T-score ≤ -2.5. 3. Treat patients diagnosed with osteoporosis or patients with osteopaenia and high fracture risk. 4. Refer

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

120. Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis

Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis UTCAT3302, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis Clinical Question Can cone beam computed tomography be considered a helpful tool in predicting osteoporosis? Clinical Bottom Line Cone beam computed tomography imaging (...) is a promising technique to predict osteoporosis. For patients who have osteoporosis, CBCT radiodensity can be a predictor of low bone mineral density (BMD). Dentists can use this as a tool to help in early diagnosis and referral of the patient to a physician to manage the case before deterioration. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Guerra/2017 6 studies, 220 patients Systematic review

2017 UTHSCSA Dental School CAT Library